title: Low contrast stimuli enhance PERG sensitivity to the visual dysfunction in Parkinson's disease.
abstract: The pattern electroretinogram (PERG) was recorded at different contrast levels (96%, 71%, 47%) in 10 Parkinson's disease patients before and during dopaminergic monotherapy. The data were compared to a control group of 8 normal subjects recorded with the same procedure. PERG P50 latency progressively increased as contrast was decreased both in normal subjects and patients; however, this trend was much more pronounced in PD patients without therapy; consequently in this group the difference between P50 latency obtained with 96% and 47% contrast was statistically significant (P = 0.01, analysis of variance corrected by post-hoc Tukey test). By contrast this was not seen in the control group. Statistical analysis (Bonferroni's t test) showed at the 47% contrast level a significant P50 latency increase (P less than 0.01) in PD patients without therapy if compared with the control group. Dopaminergic monotherapy induced a P50 latency recovery in PD patients. We conclude that low contrast stimuli enhance PERG sensitivity to the visual dysfunction of PD patients. Moreover, the effects observed after therapy confirm that abnormal contrast response functions in PD patients are linked to dopaminergic deficiency.
authors.affiliation: Istituto di Clinica delle Malattie Nervose e Mentali, Università La Sapienza, Rome, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Peppe
authors.forename: P
authors.initials: P
authors.lastname: Stanzione
authors.forename: F
authors.initials: F
authors.lastname: Pierelli
authors.forename: E
authors.initials: E
authors.lastname: Stefano
authors.forename: P A
authors.initials: PA
authors.lastname: Rizzo
authors.forename: M
authors.initials: M
authors.lastname: Tagliati
authors.forename: C
authors.initials: C
authors.lastname: Morocutti
mesh_terms: D000368:Aged; D004596:Electroretinography / Q000379:methods*; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology*
chemical_list: D007980:Levodopa